Advent, Bain Seek Full Control of Brazil's Amil

Advent International and Bain Capital are reportedly intensifying efforts to secure complete ownership of Amil, a prominent player in Brazil's healthcare sector. The private equity giants are understood to be pursuing a valuation of approximately R$17 billion (around $3.3 billion USD) for the health insurer. This push for 100% control follows protracted discussions where the primary sticking point remains the extent of ownership, rather than the overall deal value.

Sources indicate that while the initial offer from Advent and Bain Capital piqued the interest of Amil's current owner, businessman José Seripieri Filho, he has expressed a desire to retain a minority stake. However, the private equity consortium is reportedly unwilling to proceed with a deal that includes Seripieri Filho as a shareholder, signaling a firm stance on acquiring full operational and equity control. This divergence has led to ongoing negotiations concerning the precise valuation, working capital adjustments, and the overall transaction structure.

Amil's ownership history adds a layer of complexity to the current negotiations. José Seripieri Filho, the founder of insurance broker Qualicorp, acquired Amil from UnitedHealth Group in early 2024. The transaction was valued at roughly R$11 billion (approximately $2.1 billion USD), with a significant portion attributed to contingent liabilities. UnitedHealth Group's divestment from Brazil at that time resulted in a substantial financial charge, underscoring their strategic exit. Seripieri Filho has since focused on navigating regulatory challenges and mitigating the insurer's liabilities.

The proposed R$17 billion valuation represents a notable increase from the acquisition price, reflecting the progress made in stabilizing and potentially enhancing Amil's operational and financial standing. This potential upside is a key factor in Seripieri Filho's reluctance to relinquish full control. Bain Capital initially engaged with Seripieri Filho regarding a takeover last year, but those discussions did not materialize. The subsequent formation of a joint bid with Advent International revitalized the pursuit of acquiring Amil outright.

This collaboration brings together two private equity firms with established expertise in the Brazilian healthcare landscape. Advent International has a notable presence in the sector, including an investment in diagnostics firm Fleury, and recently secured significant stakes in consumer goods company Natura. Bain Capital also boasts prior experience as an owner of health insurer NotreDame Intermédica, further solidifying their credentials in this market.

The Brazilian private healthcare market, while substantial, has faced headwinds. Leading operator Hapvida, for instance, has experienced a significant decline in market capitalization over the past year, highlighting the sector's current challenges. Despite these broader market dynamics, the potential acquisition of Amil by such prominent financial sponsors suggests a belief in the company's specific turnaround potential and the long-term prospects of Brazil's healthcare services.

Market observers anticipate a resolution to these negotiations before the close of the year, although no formal deadline has been set. The successful completion of this transaction would represent a significant move within Brazil's competitive health insurance industry, potentially reshaping market dynamics.